Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment

2009 ◽  
Vol 34 (6) ◽  
pp. 693-701 ◽  
Author(s):  
Y-M. Ye ◽  
H-Y. Lee ◽  
S-H. Kim ◽  
Y-K. Jee ◽  
S-K. Lee ◽  
...  
Keyword(s):  
Asthma Control ◽  
Corticosteroid Treatment ◽  
Inhaled Corticosteroid ◽  
Pharmacogenetic Study

Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11

2008 ◽  
Vol 2 (3) ◽  
pp. 149-157 ◽  
Author(s):  
Hans Jürgen Hoffmann ◽  
Lars Peter Nielsen ◽  
Henrik Harving ◽  
John H. Heinig ◽  
Ronald Dahl
Keyword(s):  
Asthma Control ◽  
Corticosteroid Treatment ◽  
Inhaled Corticosteroid ◽  
Step Down ◽  
Low Serum

Asthma Control With Montelukast or Salmeterol As Add-On Therapy To Inhaled Corticosteroid Treatment of Asthm

CHEST Journal ◽  
2003 ◽  
Vol 124 (4) ◽  
pp. 94S ◽  
Author(s):  
David Anstatt ◽  
Felicia C. Allen-Ramey ◽  
James Korelitz ◽  
James Bethel ◽  
Shiva Sajjan ◽  
...  
Keyword(s):  
Asthma Control ◽  
Corticosteroid Treatment ◽  
Inhaled Corticosteroid

scholarly journals Variability of lung function predicts loss of asthma control following withdrawal of inhaled corticosteroid treatment

Thorax ◽  
2010 ◽  
Vol 65 (5) ◽  
pp. 403-408 ◽  
Author(s):  
C. Thamrin ◽  
D. R. Taylor ◽  
S. L. Jones ◽  
B. Suki ◽  
U. Frey
Keyword(s):  
Lung Function ◽  
Asthma Control ◽  
Corticosteroid Treatment ◽  
Inhaled Corticosteroid

Inhaled corticosteroid treatment and growth of asthmatic children seen at outpatient clinics

2006 ◽  
Vol 82 (3) ◽  
pp. 197-203 ◽  
Author(s):  
Elisete E. Arend ◽  
Gilberto B. Fischer ◽  
Márcio Debiasi ◽  
Helena Schmid
Keyword(s):  
Corticosteroid Treatment ◽  
Outpatient Clinics ◽  
Inhaled Corticosteroid ◽  
Asthmatic Children

scholarly journals Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment

2015 ◽  
Vol 32 ◽  
pp. 37-44 ◽  
Author(s):  
Ian P. Hall ◽  
Andrew V. Fowler ◽  
Abhya Gupta ◽  
Kay Tetzlaff ◽  
Michael C. Nivens ◽  
...  
Keyword(s):  
Corticosteroid Treatment ◽  
Inhaled Corticosteroid

Lessons learned from clinical trials of asthma

2019 ◽  
Vol 40 (6) ◽  
pp. 410-413
Author(s):  
Paul A. Greenberger
Keyword(s):  
Asthma Control ◽  
Severe Asthma ◽  
Immunoglobulin E ◽  
Environmental Control ◽  
Mild Asthma ◽  
Inhaled Corticosteroid ◽  
Biologic Therapies ◽  
Asthma Control Questionnaire ◽  
Exacerbation Rate ◽  
Sputum Eosinophilia

Exacerbations of persistent or intermittent asthma should be anticipated by physicians and health-care professionals. Patients who are likely to experience an exacerbation often have a history of an exacerbation in the previous year, and the absolute eosinophil count in peripheral blood is ≥ 400/μL. Similarly, expectorated or induced sputum eosinophilia of ≥2% is associated with exacerbations. These phenotypic findings have led to effective biologic therapies, which target eosinophils or immunoglobulin E or the T-helper type 2 phenotype, especially in children, adolescents, and adults with frequent exacerbations. In children, a reduced forced expiratory volume in the first second of expiration (FEV1) to forced vital capacity ratio can be associated with future exacerbations, although the FEV1 may be in the normal range, even with children who have persistent severe asthma. Asthma control questionnaires did not differentiate between children with or children without a future exacerbation. Alternatively, in adults, the lower baseline FEV1 (2.3 L [74% predicted] versus 2.5 L [78% predicted]) identified patients more likely to have a future exacerbation compared with patients who were not having an exacerbation. After correcting for FEV1, the asthma control questionnaire data were associated with exacerbations. In adolescents (ages ≥ 12 years) and adults with persistent mild asthma, most (73%) did not have sputum eosinophilia, and some of these patients responded well to the anticholinergic, tiotropium, which would argue differently from administration of an inhaled corticosteroid as first-line controller therapy. In a three-track study of patients with persistent mild asthma, as-needed budesonide-formoterol and scheduled budesonide were associated with approximately one-half of the annual exacerbation rate of as-needed albuterol. In patients with persistent moderate-to-severe asthma, tiotropium added to controller therapy caused an increase in FEV1 without improving the asthma control questionnaire findings. There were two studies that explored whether either quadrupling or quintupling the inhaled corticosteroid at the first sign of loss of control of asthma would provide meaningful reductions of severe exacerbations of asthma, but the findings did not support this strategy. Both biologic therapies and environmental control (dust mite impermeable encasings) have resulted in reductions of exacerbations in patients with persistent moderate and severe asthma.

scholarly journals Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Michael J. McGeachie ◽  
Joanne E. Sordillo ◽  
Amber Dahlin ◽  
Alberta L. Wang ◽  
Sharon M. Lutz ◽  
...  
Keyword(s):  
Asthma Control ◽  
Corticosteroid Therapy ◽  
Inhaled Corticosteroid
Sign in / Sign up

Export Citation Format

Share Document